Suppr超能文献

非恶性门静脉血栓形成的抗凝治疗是安全的,且可改善肝功能。

Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function.

作者信息

Scheiner Bernhard, Stammet Paul René, Pokorny Sebastian, Bucsics Theresa, Schwabl Philipp, Brichta Andrea, Thaler Johannes, Lampichler Katharina, Ba-Ssalamah Ahmed, Ay Cihan, Ferlitsch Arnulf, Trauner Michael, Mandorfer Mattias, Reiberger Thomas

机构信息

Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.

Vienna Hepatic Hemodynamic Laboratory, Medical University of Vienna, Vienna, Austria.

出版信息

Wien Klin Wochenschr. 2018 Jul;130(13-14):446-455. doi: 10.1007/s00508-018-1351-y. Epub 2018 Jun 18.

Abstract

BACKGROUND

Non-malignant portal vein thrombosis (PVT) is common in patients with advanced liver disease. Anticoagulation (AC) increases the chances of recanalization and may improve liver function in patients with cirrhosis.

AIM

We retrospectively assessed the course of non-malignant PVT in patients receiving AC.

METHODS

Parameters related to hepatic injury (aspartate aminotransferase [AST]/alanine aminotransferase [ALT]), severity of disease (ascites) and synthesis function (albumin) as well as AC, rates of PVT regression/progression and AC-associated complications were documented.

RESULTS

Among 122 patients with PVT, 51 patients with non-malignant PVT (27 incomplete, 24 complete) were included, 12 patients (25%) received long-term AC therapy (≥9 months) as compared to 36 patients without long-term AC. We observed a trend towards higher regression rates with long-term AC of 58% (vs. 28% without AC; p = 0.08) and lower progression rates of 25% (vs. 42% without AC; p = 0.15). In the subgroup of patients with decompensation prior to PVT diagnosis (n = 39), long-term AC (n = 10, 25.6%) resulted in a significantly higher rate of PVT regression/resolution (70% vs. 24%, p = 0.031). Interestingly, AST/ALT tended to decrease (-19%/-16%) and the proportion of patients with ascites became lower (-33%) with long-term AC (without AC: ±0%). Furthermore, there was a significant improvement in albumin levels (+9%/+3.6 g/dl) when compared to patients without long-term AC (-2%/-0.8 g/dl; p = 0.04). Additionally, 10 patients were treated with direct oral anticoagulants (DOACs) for splanchnic vein thrombosis. Importantly, there were no AC-associated bleeding events in patients with conventional AC and one bleeding event in patients with DOAC treatment (10%).

CONCLUSION

Our findings support anticoagulation in patients with non-malignant PVT, since AC seems safe and associated with superior PVT regression rates and might also decrease hepatic injury and improve liver synthesis.

摘要

背景

非恶性门静脉血栓形成(PVT)在晚期肝病患者中很常见。抗凝治疗(AC)可增加再通的机会,并可能改善肝硬化患者的肝功能。

目的

我们回顾性评估了接受AC治疗的非恶性PVT患者的病程。

方法

记录与肝损伤相关的参数(天冬氨酸转氨酶[AST]/丙氨酸转氨酶[ALT])、疾病严重程度(腹水)和合成功能(白蛋白)以及AC、PVT消退/进展率和AC相关并发症。

结果

在122例PVT患者中,纳入了51例非恶性PVT患者(27例不完全性,24例完全性),12例患者(25%)接受了长期AC治疗(≥9个月),而36例患者未接受长期AC治疗。我们观察到长期AC治疗的消退率有升高趋势,为58%(未接受AC治疗的为28%;p = 0.08),进展率降低,为25%(未接受AC治疗的为42%;p = 0.15)。在PVT诊断前有失代偿的患者亚组(n = 39)中,长期AC治疗(n = 10,25.6%)导致PVT消退/溶解率显著更高(70%对24%,p = 0.031)。有趣的是,长期AC治疗时AST/ALT有下降趋势(-19%/-16%),腹水患者比例降低(-33%)(未接受AC治疗的患者:±0%)。此外,与未接受长期AC治疗的患者相比(-2%/-0.8 g/dl;p = 0.04),白蛋白水平有显著改善(+9%/+3.6 g/dl)。另外,10例患者接受了直接口服抗凝剂(DOACs)治疗内脏静脉血栓形成。重要的是,接受传统AC治疗的患者未发生AC相关出血事件,接受DOAC治疗的患者发生了1例出血事件(10%)。

结论

我们的研究结果支持对非恶性PVT患者进行抗凝治疗,因为AC似乎是安全的,且与更高的PVT消退率相关,还可能减少肝损伤并改善肝脏合成功能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12cd/6061656/703602202382/508_2018_1351_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验